JY025
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for JY025, covering 2021-05-10 to 2021-05-10. Get the full timeline:
Most recent: Clinical Trial Update: JY025 is a First-line Treatment for EGFR Mutated NSCLC Phase II and III Clinical Trials of Efficacy and Safety [Phase 2, Phase 3]